114 related articles for article (PubMed ID: 31250159)
1. RRx-001 protects normal tissues but not tumors via Nrf2 induction and Bcl-2 inhibition.
Oronsky B; Scribner C; Aggarwal R; Cabrales P
J Cancer Res Clin Oncol; 2019 Aug; 145(8):2045-2050. PubMed ID: 31250159
[TBL] [Abstract][Full Text] [Related]
2. Nrf2 activity as a potential biomarker for the pan-epigenetic anticancer agent, RRx-001.
Ning S; Sekar TV; Scicinski J; Oronsky B; Peehl DM; Knox SJ; Paulmurugan R
Oncotarget; 2015 Aug; 6(25):21547-56. PubMed ID: 26280276
[TBL] [Abstract][Full Text] [Related]
3. The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry.
Zhao H; Ning S; Nolley R; Scicinski J; Oronsky B; Knox SJ; Peehl DM
Clin Epigenetics; 2017; 9():4. PubMed ID: 28149332
[TBL] [Abstract][Full Text] [Related]
4. RRx-001 protects against cisplatin-induced toxicities.
Oronsky B; Reid TR; Larson C; Carter CA; Brzezniak CE; Oronsky A; Cabrales P
J Cancer Res Clin Oncol; 2017 Sep; 143(9):1671-1677. PubMed ID: 28417195
[TBL] [Abstract][Full Text] [Related]
5. RRx-001 Increases Erythrocyte Preferential Adhesion to the Tumor Vasculature.
Jani VP; Asaro R; Oronsky B; Cabrales P
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946824
[TBL] [Abstract][Full Text] [Related]
6. Nrf2 protein up-regulates antiapoptotic protein Bcl-2 and prevents cellular apoptosis.
Niture SK; Jaiswal AK
J Biol Chem; 2012 Mar; 287(13):9873-9886. PubMed ID: 22275372
[TBL] [Abstract][Full Text] [Related]
7. Antioxidant tert-butylhydroquinone ameliorates arsenic-induced intracellular damages and apoptosis through induction of Nrf2-dependent antioxidant responses as well as stabilization of anti-apoptotic factor Bcl-2 in human keratinocytes.
Duan X; Li J; Li W; Xing X; Zhang Y; Li W; Zhao L; Sun G; Gao XH; Li B
Free Radic Biol Med; 2016 May; 94():74-87. PubMed ID: 26878773
[TBL] [Abstract][Full Text] [Related]
8. Paeoniflorin protects Schwann cells against high glucose induced oxidative injury by activating Nrf2/ARE pathway and inhibiting apoptosis.
Yang X; Yao W; Shi H; Liu H; Li Y; Gao Y; Liu R; Xu L
J Ethnopharmacol; 2016 Jun; 185():361-9. PubMed ID: 26979341
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of Action of Nigella sativa on Human Colon Cancer Cells: the Suppression of AP-1 and NF-κB Transcription Factors and the Induction of Cytoprotective Genes.
Elkady AI; Hussein RA; El-Assouli SM
Asian Pac J Cancer Prev; 2015; 16(17):7943-57. PubMed ID: 26625825
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic effects of RRx-001: a possible unifying mechanism of anticancer activity.
Zhao H; Ning S; Scicinski J; Oronsky B; Knox SJ; Peehl DM
Oncotarget; 2015 Dec; 6(41):43172-81. PubMed ID: 26657731
[TBL] [Abstract][Full Text] [Related]
11. Cancer Cell Growth Is Differentially Affected by Constitutive Activation of NRF2 by KEAP1 Deletion and Pharmacological Activation of NRF2 by the Synthetic Triterpenoid, RTA 405.
Probst BL; McCauley L; Trevino I; Wigley WC; Ferguson DA
PLoS One; 2015; 10(8):e0135257. PubMed ID: 26301506
[TBL] [Abstract][Full Text] [Related]
12. A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells.
Das DS; Ray A; Das A; Song Y; Tian Z; Oronsky B; Richardson P; Scicinski J; Chauhan D; Anderson KC
Leukemia; 2016 Nov; 30(11):2187-2197. PubMed ID: 27118403
[TBL] [Abstract][Full Text] [Related]
13. RRx-001, an epigenetic-based radio- and chemosensitizer, has vascular normalizing effects on SCCVII and U87 tumors.
Oronsky B; Scicinski J; Cabrales P; Minchinton A
Clin Epigenetics; 2016; 8():53. PubMed ID: 27175220
[TBL] [Abstract][Full Text] [Related]
14. Hepatoprotective effect of rhein against methotrexate-induced liver toxicity.
Bu T; Wang C; Meng Q; Huo X; Sun H; Sun P; Zheng S; Ma X; Liu Z; Liu K
Eur J Pharmacol; 2018 Sep; 834():266-273. PubMed ID: 30031796
[TBL] [Abstract][Full Text] [Related]
15. RRx-001, a novel clinical-stage chemosensitizer, radiosensitizer, and immunosensitizer, inhibits glucose 6-phosphate dehydrogenase in human tumor cells.
Oronsky B; Scicinski J; Reid T; Oronsky A; Carter C; Oronsky N; Cabrales P
Discov Med; 2016 Apr; 21(116):251-65. PubMed ID: 27232511
[TBL] [Abstract][Full Text] [Related]
16. Targeting tumor hypoxia with the epigenetic anticancer agent, RRx-001: a superagonist of nitric oxide generation.
Fens MH; Cabrales P; Scicinski J; Larkin SK; Suh JH; Kuypers FA; Oronsky N; Lybeck M; Oronsky A; Oronsky B
Med Oncol; 2016 Aug; 33(8):85. PubMed ID: 27377482
[TBL] [Abstract][Full Text] [Related]
17. Indazolo[3,2-b]quinazolinones Attack Hepatocellular Carcinoma Hep3B Cells by Inducing Mitochondrial-Dependent Apoptosis and Inhibition of Nrf2/ARE Signaling Pathway.
Zhang Y; Qiao R; He D; Zhao Z; Yang S; Zou H; Zhang X; Wu M; Chen J; Chen P
Curr Mol Med; 2016; 16(9):820-828. PubMed ID: 27894242
[TBL] [Abstract][Full Text] [Related]
18. Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2.
Tung MC; Lin PL; Wang YC; He TY; Lee MC; Yeh SD; Chen CY; Lee H
Oncotarget; 2015 Dec; 6(39):41692-705. PubMed ID: 26497680
[TBL] [Abstract][Full Text] [Related]
19. Proteasome inhibition induces a p38 MAPK pathway-dependent antiapoptotic program via Nrf2 in thyroid cancer cells.
Du ZX; Yan Y; Zhang HY; Liu BQ; Gao YY; Niu XF; Meng X; Wang HQ
J Clin Endocrinol Metab; 2011 May; 96(5):E763-71. PubMed ID: 21346076
[TBL] [Abstract][Full Text] [Related]
20. Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical Development.
Oronsky B; Guo X; Wang X; Cabrales P; Sher D; Cannizzo L; Wardle B; Abrouk N; Lybeck M; Caroen S; Oronsky A; Reid TR
J Med Chem; 2021 Jun; 64(11):7261-7271. PubMed ID: 34043360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
